Key facts
- Oligomerix’s last known valuation is $11.1M (Mar 2022).
- It has raised $7.7M across 2 recorded rounds; the latest was Seed Round ($2.4M) in Mar 2022.
- Notable investors include Counterview Capital, Alzheimers Drug Discovery Foundation, Durand Venture Associates, National Institute On Aging, Wheatley Partners.
- Oligomerix has filed 5 Form Ds with the SEC since 2012, most recently Dec 2024 ($75K sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Oligomerix
Funding rounds
2 roundsAbout Oligomerix
Developer of small molecule therapeutics designed to treat Alzheimer's disease with an upstream approach. The company specializes in disease-modifying therapeutics for neurodegenerative diseases characterized by aberrant tau protein, ranging from rare tauopathies such as progressive supranuclear palsy and frontotemporal dementia, enabling physicians to treat their patients in an enhanced way.
- Sector
- Healthcare
- HQ
- Bronx, NY, United States
- Founded
- 2006
- Employees
- 11
- Website
- oligomerix.com/
- Ownership
- Privately Held (backing)
Oligomerix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Oligomerix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Oligomerix in its N-PORT filings yet. We sweep new filings monthly.